Nobel prize in chemistry awarded for pioneering work on enzymes and antibodies

Three researchers who “harnessed the power of evolution” to produce enzymes and antibodies that have led to a new best-selling drug and biofuels won the Nobel Prize in chemistry.
Dr. Frances Arnold of the California Institute of Technology was awarded half of the 9-mn Kronor ($1.01-mn) prize, while the other half will be shared by Dr. George Smith of the University of Missouri and Dr. Gregory Winter of the MRC molecular biology lab in Cambridge, England.
Since 1901, when the Nobel Prize in Chemistry was first awarded, 177 people have captured the honour. This year Dr. Arnold became only the fifth woman to be awarded the prize.
The Royal Swedish Academy of Sciences, which chose the winners, said Dr. Arnold, 62, conducted the first directed evolution of enzymes, whose uses include “more environmentally friendly manufacturing of chemical substances such as pharmaceuticals and the production of renewable fuels.”
Dr. Smith, 77, was honoured for developing a method, known as phage display, in which a virus that infects bacteria can be used to evolve new proteins. Dr. Winter won for evolving antibodies through phage display to combat autoimmune diseases and in some cases, cure metastatic cancer.
The first pharmaceutical based on Dr. Winter’s work was approved for use in 2002 and is employed to treat rheumatoid arthritis, psoriasis and inflammatory bowel diseases, the academy said. The chemical name of the drug is adalimumab, which has several trade named including Humira, one of the top-selling drugs in the world.
Looking for chemical products? Let suppliers reach out to you!
2026-07-07
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Faces a Compliance Test
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
Recommend Reading
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Trump Sets 19 Percent Tariff on All Indonesian Exports to US $1.9 Billion Seafood Trade Faces Uncertainty
-
Asahi Kasei Plans to Double Photosensitive Polyimide Production Capacity by 2030
-
This Week’s Petrocoke Market Prices Rise
-
IMM PE Plans to Partially Sell A’pieu Cosmetics Brand
-
This week, the Chinese epichlorohydrin market continues to maintain a stable operation trend (6.15-6.18)